VivoSeq
Other

CML

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

CML is an early-stage landscape with 0 programs across 3 companies. The most active players are Novartis, Bristol-Myers Squibb, Korea Otsuka Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

63/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalK

Korea Otsuka Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

17

clinical trials

Unknown status6 · 35%
Completed5 · 29%
Terminated2 · 12%
Withdrawn1 · 6%
Recruiting1 · 6%
Active, not recruiting1 · 6%
Other1 · 6%

Clinical Trials

Trial Activity

17 trials

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
Recruiting·Novartis logoNovartis·Phase 2·NCT06514534·20 enrolled
Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)
Active, not recruiting·FFundacion CRIS de Investigación para Vencer el Cáncer·Phase 2·NCT04160546·80 enrolled
Tasigna in Glivec-resistant or Intolerant Patients in CML
Completed·Novartis logoNovartis·Phase 4·NCT01206088·93 enrolled
Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients
Completed·UUniversity of Milano Bicocca·Phase 4·NCT01578213·112 enrolled
Rollover Study of BMS-354825 in Patients With CML and Ph+ALL
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT01030718·54 enrolled
Nilotinib in PH+, BCR-, ABL+ CML Patients
Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 3·NCT01535391·109 enrolled
Study of BMS-354825 in Subjects With CML Who Are Resistant to or Intolerant of Imatinib or Ph+All in Japan
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1/2·NCT00337454·48 enrolled
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00499889·42 enrolled
Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
Terminated·UUniversity of Massachusetts, Worcester·Phase 1·NCT01130688·2 enrolled
IIT PH1 KDS-1001 in Patients With CML
Withdrawn·—·Phase 1·NCT04808115
Radotinib as 3rd or Later Line Therapy in CP-CML
Unknown status·UUlsan University Hospital·Phase 2·NCT02422719·73 enrolled
Early Conversion of Dasatinib in CML-CP Patients
Unknown status·NNanfang Hospital, Southern Medical University·N/A·NCT04136015·200 enrolled
Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients
Unknown status·FFirst Affiliated Hospital of Harbin Medical University·Phase 3·NCT03515018·60 enrolled
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
Unknown status·SShenzhen Second People's Hospital·Phase 4·NCT04677439·200 enrolled
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
Unknown status·SSheba Medical Center·Phase 3·NCT00297570·90 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)